<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03366766</url>
  </required_header>
  <id_info>
    <org_study_id>17P.556</org_study_id>
    <nct_id>NCT03366766</nct_id>
  </id_info>
  <brief_title>Nivolumab, Cisplatin, and Pemetrexed Disodium or Gemcitabine Hydrochloride in Treating Patients With Stage I-IIIA Non-small Cell Lung Cancer That Can Be Removed by Surgery</brief_title>
  <official_title>Nivolumab Plus Cisplatin/Pemetrexed or Cisplatin/Gemcitabine as Induction in Resectable Non-Small Cell Lung Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sidney Kimmel Cancer Center at Thomas Jefferson University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Thomas Jefferson University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This phase II trial studies how well Nivolumab, Cisplatin, and Pemetrexed Disodium or&#xD;
      Gemcitabine Hydrochloride in treating patients with stage I-IIIA non-small cell lung cancer&#xD;
      that can be removed by surgery. Monoclonal antibodies, such as Nivolumab, may interfere with&#xD;
      the ability of tumor cells to grow and spread. Drugs used in chemotherapy, such as Cisplatin&#xD;
      and Pemetrexed Disodium or Gemcitabine Hydrochloride, work in different ways to stop the&#xD;
      growth of tumor cells, either by killing the cells, by stopping them from dividing, or by&#xD;
      stopping them from spreading. Giving Nivolumab, Cisplatin, and Pemetrexed Disodium or&#xD;
      Gemcitabine Hydrochloride may work better in treating patients with non-small cell lung&#xD;
      cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:&#xD;
&#xD;
      I. To estimate major pathologic response (mpCR) in patients with newly diagnosed and&#xD;
      untreated non-small cell lung cancer (NSCLC) stage I-IIIA treated with three courses of&#xD;
      induction nivolumab added to either cisplatin/pemetrexed or cisplatin/gemcitabine prior to&#xD;
      surgery.&#xD;
&#xD;
      SECONDARY OBJECTIVES:&#xD;
&#xD;
      I. Safety. II. Complete pathologic response at all sites of disease. III. Major pathologic&#xD;
      response rate at primary site. IV. Clinical complete response rate. V. 1 year progression&#xD;
      free survival (PFS). VI. Overall survival.&#xD;
&#xD;
      TERTIARY OBJECTIVES:&#xD;
&#xD;
      I. To explore whether PDL1 expression is associated with treatment response. II. To explore&#xD;
      whether there is a net change in the Th1/Th2 ratio (IFN-gamma, IL-4, IL10, etc.) or cell&#xD;
      subset frequencies (M2 monocytes, myeloid-derived suppressor cells, etc.) within a patient's&#xD;
      peripheral blood either at baseline or in response to treatment is associated with treatment&#xD;
      response.&#xD;
&#xD;
      III. To explore whether exosomes or other immune related serum biomarkers change after&#xD;
      combination therapy.&#xD;
&#xD;
      IV. To explore the predictive value of serial cell free deoxyribonucleic acid (DNA) levels&#xD;
      and response.&#xD;
&#xD;
      V. PD-L1 assessment in tumor.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">December 20, 2017</start_date>
  <completion_date type="Anticipated">July 2022</completion_date>
  <primary_completion_date type="Anticipated">July 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Major pathologic response (mpCR) defined as &lt; 10% viable tumor</measure>
    <time_frame>Up to 63 days</time_frame>
    <description>A minimax Simon two-stage design will be used. The mpCR rate and its associated score 95% confidence interval will be estimated using the methods</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of adverse events according to Common Terminology Criteria for Adverse Events (CTCAE) version 4.03</measure>
    <time_frame>Up to 6 months</time_frame>
    <description>Safety data will be summarized descriptively.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression free survival</measure>
    <time_frame>At 1 year</time_frame>
    <description>The distribution of progression-free survival will be estimated using the Kaplan-Meier method.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>Up to 6 months</time_frame>
    <description>The distribution of overall survival will be estimated using the Kaplan-Meier method.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall clinical response</measure>
    <time_frame>Up to 6 months</time_frame>
    <description>Will be summarized by presence of baseline measurable disease.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">14</enrollment>
  <condition>Non-Squamous Non-Small Cell Lung Carcinoma</condition>
  <condition>Stage I Non-Small Cell Lung Cancer</condition>
  <condition>Stage IA Non-Small Cell Lung Carcinoma</condition>
  <condition>Stage IB Non-Small Cell Lung Carcinoma</condition>
  <condition>Stage II Non-Small Cell Lung Cancer</condition>
  <condition>Stage IIA Non-Small Cell Lung Carcinoma</condition>
  <condition>Stage IIB Non-Small Cell Lung Carcinoma</condition>
  <condition>Stage IIIA Non-Small Cell Lung Cancer</condition>
  <arm_group>
    <arm_group_label>Cohort I (nivolumab, cisplatin, pemetrexed disodium)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with non-squamous lung cancer receive nivolumab IV over 30 minutes, cisplatin IV over 60-120 minutes, and pemetrexed disodium IV over 10 minutes on day 1. Courses repeat every 3 weeks for up to 9 weeks in the absence of disease progression or unacceptable toxicity</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort I (nivolumab, cisplatin, gemcitabine hydrochloride)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with squamous lung cancer receive nivolumab IV over 30 minutes on day 1, cisplatin IV over 60-120 minutes on day 1, and gemcitabine hydrochloride IV over 1 hour on days 1 and 8. Courses repeat every 3 weeks for up to 9 weeks in the absence of disease progression or unacceptable toxicity.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Nivolumab</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Cohort I (nivolumab, cisplatin, gemcitabine hydrochloride)</arm_group_label>
    <arm_group_label>Cohort I (nivolumab, cisplatin, pemetrexed disodium)</arm_group_label>
    <other_name>BMS-936558</other_name>
    <other_name>NIVO</other_name>
    <other_name>Opdivo</other_name>
    <other_name>ONO-4538</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cisplatin</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Cohort I (nivolumab, cisplatin, pemetrexed disodium)</arm_group_label>
    <other_name>(SP-4-2)-Diamminedichloroplatinum</other_name>
    <other_name>Abiplatin</other_name>
    <other_name>Blastolem</other_name>
    <other_name>Briplatin</other_name>
    <other_name>(CDDP) Cis-diammine-dichloroplatinum</other_name>
    <other_name>Cis-dichloroammine Platinum (II)</other_name>
    <other_name>Metaplatin</other_name>
    <other_name>Plastistil</other_name>
    <other_name>Platinol</other_name>
    <other_name>Platinex</other_name>
    <other_name>Platinol-AQ VHA Plus</other_name>
    <other_name>Peyrone's Salt</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pemetrexed Disodium</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Cohort I (nivolumab, cisplatin, pemetrexed disodium)</arm_group_label>
    <other_name>Alimta</other_name>
    <other_name>N-[4-[2-(2-Amino-4,7-dihydro-4-oxo-1H-pyrrolo[2,3-d]pyrimidin-5-yl)ethyl]benzoyl]-L-glutamic Acid Disodium Salt</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gemcitabine Hydrochloride</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Cohort I (nivolumab, cisplatin, gemcitabine hydrochloride)</arm_group_label>
    <other_name>Hydrochloride</other_name>
    <other_name>Difluorodeoxycytidine Hydrochloride</other_name>
    <other_name>Gemzar</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Pathologically confirmed non small cell lung cancer (NSCLC), not previously treated,&#xD;
             with a plan to undergo surgery&#xD;
&#xD;
          -  Stage I-IIIA (stage I tumors must be &gt;= 4 cm) per AJCC 8th edition&#xD;
&#xD;
          -  Tumor sample must be available for PD-L1 testing; archival tissue within 3 months of&#xD;
             study enrollment will be used; if archival tissue is unavailable, a fresh biopsy will&#xD;
             be taken&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) performance status 0-1&#xD;
&#xD;
          -  While blood cells 2000/ul or more&#xD;
&#xD;
          -  Absolute neutrophil count 1500/ul or more&#xD;
&#xD;
          -  Platelets 100,000/ul or more&#xD;
&#xD;
          -  Hemoglobin 9 g/dl or more; (transfusion permitted)&#xD;
&#xD;
          -  Bilirubin less than or equal to 1.5 x the upper limit of normal (except subjects with&#xD;
             Gilbert syndrome, who can have total bilirubin &lt; 3 mg/dl)&#xD;
&#xD;
          -  Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) less than or equal&#xD;
             to 3 x the upper limit of normal&#xD;
&#xD;
          -  Glomerular filtration rate (GFR) greater than or equal to 40 ml/min using the&#xD;
             Cockcroft-Gault formula or serum creatinine less than or equal to 1.5 x (ULN) upper&#xD;
             limit of normal&#xD;
&#xD;
          -  Women of reproductive potential should have a negative serum or urine pregnancy test&#xD;
             (minimum sensitivity 25 IU/L or equivalent units of human chorionic gonadotropin&#xD;
             [HCG]) within 21 days of the study enrollment&#xD;
&#xD;
          -  Women of reproductive potential must use highly effective contraception methods to&#xD;
             avoid pregnancy for 23 weeks after the last dose of study drugs; &quot;women of&#xD;
             reproductive potential&quot; is defined as any female who has experienced menarche and who&#xD;
             has not undergone surgical sterilization (hysterectomy or bilateral oophorectomy) or&#xD;
             who is not postmenopausal; menopause is defined clinically as 12 months of amenorrhea&#xD;
             in a woman over 45 in the absence of other biological or physiological causes; in&#xD;
             addition, women under the age of 55 must have a documented serum follicle stimulating&#xD;
             hormone (FSH) level more than 40 mIU/mL&#xD;
&#xD;
          -  Men of reproductive potential who are sexually active with women of reproductive&#xD;
             potential must use any contraceptive method with a failure rate of less than 1% per&#xD;
             year; men who are receiving the study medications will be instructed to adhere to&#xD;
             contraception for 31 weeks after the last dose of study drugs; men who are azoospermic&#xD;
             do not require contraception&#xD;
&#xD;
          -  All subjects must be able to comprehend and sign a written informed consent document&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients who have participated in a study with an investigational agent or device&#xD;
             within 2 weeks of enrollment&#xD;
&#xD;
          -  Any prior radiotherapy to the lung&#xD;
&#xD;
          -  Any prior treatment for NSCLC&#xD;
&#xD;
          -  Epidermal growth factor receptor (EGFR) or alkaline phosphatase (ALK) activating&#xD;
             alteration&#xD;
&#xD;
          -  Any prior therapy with anti-PD-1, anti-PD-L2, anti-CTLA-4 antibody, or any other&#xD;
             antibody or drug specifically targeting T-cell co-stimulation or immune checkpoint&#xD;
             pathways&#xD;
&#xD;
          -  Any history of a sever hypersensitivity reaction to any monoclonal antibody&#xD;
&#xD;
          -  Any history of allergy to the study drug components&#xD;
&#xD;
          -  Any concurrent malignancies- exceptions include- basal cell carcinoma of the skin,&#xD;
             squamous cell carcinoma of the skin, superficial bladder cancer or in situ cervical&#xD;
             cancer that has undergone potentially curative therapy; patients with a history of&#xD;
             other prior malignancy must have been treated with curative intent and must have&#xD;
             remained disease-free for 3 years post-diagnosis&#xD;
&#xD;
          -  Participants with an active autoimmune disease or any other condition requiring&#xD;
             systemic treatment with either corticosteroids within 14 days (&gt; 10 mg daily&#xD;
             prednisone equivalent) or other immunosuppressive medications within 30 days of&#xD;
             randomization. Inhaled or topical steroids, and adrenal replacement steroid doses &gt; 10&#xD;
             mg daily prednisone equivalent, are permitted in the absence of active autoimmune&#xD;
             disease.&#xD;
&#xD;
          -  Participants with type I diabetes mellitus, hypothyroidism only requiring hormone&#xD;
             replacement, skin disorders (such as vitiligo, psoriasis, or alopecia) not requiring&#xD;
             systemic treatment, or conditions not expected to recur in the absence of an external&#xD;
             trigger are permitted to enroll.• Patients with evidence of interstitial lung disease&#xD;
             or active, non-infectious pneumonitis. Patients with a history of interstitial lung&#xD;
             disease or non-infectious pneumonitis requiring treatment with steroids are also&#xD;
             excluded.&#xD;
&#xD;
          -  Patients with a known human immunodeficiency virus infection (HIV 1/2 antibodies) or&#xD;
             acquired immunodeficiency syndrome (HIV/AIDS), active hepatitis B (e.g., hepatitis B&#xD;
             surface antigen [HBsAg] reactive) or hepatitis C (e.g., hepatitis C virus [HCV]&#xD;
             ribonucleic acid [RNA] [qualitative] is detected)&#xD;
&#xD;
          -  Patients who have received a live vaccine within 30 days prior initiation of the&#xD;
             systemic regimen&#xD;
&#xD;
          -  Patients must not be receiving any other investigational agents&#xD;
&#xD;
          -  Patients with uncontrolled intercurrent illnesses including, but not limited to an&#xD;
             active infection requiring systemic therapy or a known psychiatric or substance abuse&#xD;
             disorder(s) that would interfere with cooperation with the requirements of the trial&#xD;
&#xD;
          -  Women must not be pregnant (as above) or breastfeeding&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Rita Axelrod, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Sidney Kimmel Cancer Center at Thomas Jefferson University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Abington Hospital - Jefferson Health</name>
      <address>
        <city>Abington</city>
        <state>Pennsylvania</state>
        <zip>19001</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sidney Kimmel Cancer Center at Thomas Jefferson University</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19107</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.kimmelcancercenter.org/cancer-center.html</url>
    <description>Sidney Kimmel Cancer Center at Thomas Jefferson University</description>
  </link>
  <link>
    <url>http://hospitals.jefferson.edu/</url>
    <description>Thomas Jefferson University Hospital</description>
  </link>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>December 4, 2017</study_first_submitted>
  <study_first_submitted_qc>December 4, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">December 8, 2017</study_first_posted>
  <last_update_submitted>August 31, 2021</last_update_submitted>
  <last_update_submitted_qc>August 31, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 1, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gemcitabine</mesh_term>
    <mesh_term>Cisplatin</mesh_term>
    <mesh_term>Nivolumab</mesh_term>
    <mesh_term>Pemetrexed</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

